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Background: Single-strand conformational polymorphism (SSCP) is still a frequently used genotyping method
across different fields for the detection of single nucleotide polymorphisms (SNPs) due to its simplicity, requirement
for basic equipment accessible in most laboratories and low cost. This technique was previously used to detect
rs4354668:A > C (g.-181A > C) SNP in the promoter of astroglial glutamate transporter (EAAT2) and the same
approach was initially used here to investigate this promoter region in a cohort of newborns.
Results: Unexpectedly, four distinct DNA migration patterns were identified by SSCP. Sanger sequencing revealed
two additional SNPs: g.-200C > A and g.-168C > T giving a rise to a total of ten EAAT2 promoter variants. SSCP failed
to distinguish these variants reliably and thus pyrosequencing assays were developed. g.-168C > T was found in
heterozygous form in one infant only with minor allele frequency (MAF) of 0.0023. In contrast, g.-200C > A and
-181A > C were more common (with MAF of 0.46 and 0.49, respectively) and showed string evidence of linkage
disequilibrium (LD). In a systematic comparison, 16% of samples were miss-classified by SSCP with 25-31% errors
in the identification of the wild-type and homozygote mutant genotypes compared to pyrosequencing or Sanger
sequencing. In contrast, SSCP and pyrosequencing of an unrelated single SNP (rs1835740:C > T), showed 94%
concordance.
Conclusion: Our data suggest that SSCP cannot always detect reliably several closely located SNPs. Furthermore,
caution is needed in the interpretation of the association studies linking only one of the co-inherited SNPs in the
EAAT2 promoter to human diseases.
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Genetic analysis is one of the fastest-growing areas
of clinical diagnostics. Changes to a single nucleotide,
known as single nucleotide polymorphism (SNP) is one
of the major types of variants identified in the human
genome. On average, in the human genome SNPs are
distributed at 1 SNP per 1000 base pairs [1,2]. Some of
these inherited SNPs play an important role in human
diseases, while others are less relevant clinically and are
phenotypically silent.
PCR amplification followed by Sanger DNA sequencing
is one of the most commonly used methods of identifying
SNPs in a sample cohort [3,4]. However, the cost per sam-
ple is still relatively high [5] and typically the sequencing
run length is ~3 hours (based on genotyping ~700 bp
amplicon using capillary array electrophoresis technology)
[6]. Due to these drawbacks single-strand conformation
polymorphism (SSCP) is still very frequently used across
many different fields for SNP detection [7-15]. SSCP is a
rapid, reproducible and quite simple method that does not
require specialised expensive equipment or reagents. The
SSCP process involves PCR amplification of the target
fragment, denaturation of the double-stranded PCR
product with heat and formamide and electrophoresis
on a non-denaturing polyacrylamide gel. During elec-
trophoresis the single-stranded DNA (ssDNA) frag-
ments fold into three-dimensional shape depending on
their primary sequence [7]. DNA fragments can then be
genotyped as a result of their different migration pat-
terns and then confirmed by Sanger sequencing. SSCP
sensitivity varies considerably from 70% to 95% [16-19].
The disadvantages of this technique are that it is rela-
tively labour intensive, low throughput and requires
Sanger sequencing of a representative sample cohort to
confirm the nucleotide sequence.
Pyrosequencing [20], a non-gel based, real-time, DNA
sequencing-by-synthesis technique that is based on the
luminometric detection of released pyrophosphate (PPi)
during nucleotide incorporation, has also been used
extensively for sample genotyping [21-26]. Pyrosequencing
relies on a cascade of enzymatic reactions that yields
detectable light, which is proportional to the incorpo-
rated nucleotides. The resulting pyrograms produce
peak patterns in short stretches of the DNA sequence
analysed, which vary between genotypes, and can
distinguish between the different alleles at a named
position. A large number of samples can therefore be
analysed in a cost and time effective manner.
In this study, we investigated a previously identified
SNP (rs4354668:A > C; [11]) in the promoter of the
astroglial glutamate transporter EAAT2 (SLC1A2) at
position -181bp (g.-181A >C) in genomic DNA of newborn
infants. The rational for looking at this particular SNP
was that previous studies using SSCP found associationof this SNP with increased extracellular glutamate levels
and neurodegeneration in adult stroke patients [11]; with
a higher risk of relapsing multiple sclerosis [27] and the
progression of migraines into chronic daily headaches
[28]. Unexpectedly, we identified two additional SNPs
in the EAAT2 promoter; g.-200C > A and g.-168C > T.
The g.-168C > T SNP was only found in one individual
in a heterozygous form in the entire cohort. In contrast,
g.-200C >A and g.-181A > C sequence variants were much
more common and they were in Linkage Disequilibrium
(LD). SSCP was not discriminatory enough to clearly show
differences between the various genotypes and 31% of
homozygote mutants (mutant/mutant; MT/MT) and 25%
wild-type (WT/WT) genotypes were identified incorrectly
using this technique when compared to sequencing data.
In contrast, pyrosequencing detected all naturally occur-
ring variants in the highly GC-rich region and showed
100% concordance with Sanger sequencing suggesting
that it can be used successfully to detect closely posi-
tioned and linked SNPs. Our data also indicate that the
interpretation of the studies [11] attributing a causal
link between g.-181A > C and adult neurological diseases
is incomplete as the SNP was potentially misclassified and
the LD with another SNPs not considered.
Methods
Sample collection and processing
Newborn dried blood spots (DBS) were collected from
predominantly Caucasian infants (91.6% white, 8.4% non-
white) born in the greater Bristol area (UK) participating
in an association study to investigate the genetic back-
ground of newborn infants to white matter brain injury.
The study received ethical approval in April 2008 from the
National Research Ethics Service, UK (REC reference
number 10/H0106/10 [29]). Samples, collected from 239
infants within the past 3-22 years, were used in the study.
All blood spot screening cards were stored in the biobank
in boxes at room temperature. Whole blood samples were
collected from nine healthy adult volunteers to optimise
protocols used in the study. Genomic DNA was isolated
and quantified as we described previously [29].
PCR amplification of EAAT2 promoter for SSCP analysis
Previously described primers EAAT2F and EAAT2R
were used to amplify the EAAT2 promoter fragment
(GeneBank accession AF510107.1; Figure 1 and Table 1
[11]). All PCR reactions were carried out for 35 cycles in
a total volume of 25 μl, containing 1× high fidelity reac-
tion buffer - (500 mM KCl, 100 mM Tris-HCl, pH 8.3),
1 mM of MgCl2, 200 μM of each dNTP, 100 pmol of
each oligonucleotide primer, 1 unit of high fidelity Taq
Polymerase (FastStart High Fidelity Taq Polymerase,
Roche Diagnostics Limited, West Sussex, UK) and 2 μl
(~1-30 ng) of gDNA. Additionally, a final concentration
Figure 1 Promoter sequence of the human EAAT2 (Accession AF510107.1). The primers and the positions of the three SNPs at -200bp
(g.-200C > A), -181bp (g.-181A > C) and -168bp (g.-168C > T) are indicated. Numbering is relative to the transcription start site. Primers EAAT2F and
EAAT2R were used for standard PCR and Sanger sequencing while EAAT2PyroF-BIO and EAAT2Pyro-R were used to generate biotinylated PCR
products and EAAT2PyroSeq1 and EAAT2PyroSeq2 for pyrosequencing (see also Table 1).
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West Sussex, UK) was added to each reaction. Reaction
parameters were 95°C for 5 min followed by 35 cycles of
95°C for 30 s, 60°C for 45 s and 72°C for 1 min. A final
extension at 72°C was carried out for 10 min.
SSCP analysis
SSCP was performed as previously described [8]. PCR
samples were resolved on 0.5× acrylamide gels containing
12.5 ml MDE® (Mutation Detection Enhancement) gel
solution (Lonza Group Ltd., Basel, Switzerland), 3 ml
of 10× TBE (Tris/Borate/EDTA, pH 8.3) buffer, 34.28
ml deionised water, 20 μl tetramethylethylenediamine
(TEMED; Sigma-Aldrich, St Louis, Missouri, UK) and
200 μl of freshly prepared 10% ammonium persulfate
(APS; Sigma-Aldrich, St Louis, Missouri, UK). PCR
samples were prepared for electrophoresis as follows; 3 μl
of PCR product was mixed with 7 μl of denaturing load-
ing buffer (95% formamide, 0.025% bromophenol blue,
0.025% xylene cyanol and 20 mM EDTA) (all reagents
from Sigma-Aldrich, St Louis, Missouri, UK). The mix-
ture was heated to 95°C for 5 min, rapidly cooled on ice
and then 10 μl was loaded and run for 30 min at 300 V.
The voltage was then reduced to 150 V and the DNA
strands separated for 14 h at room temperature (~20°C).Table 1 Pyrosequencing primers and conditions used in the s
Oligonucleotide Sequence 5′-3′ Pro
EAAT2F GGGGCTAAACCTTGCAATCC
EAAT2R CTGCCACCTGTGCTTTGC
EAAT2PyroF-BIO GGGGCTAAACCTTGCAATC
EAAT2PyroR GAGTGGCGGGAGCAGAGA
EAAT2PyroSeq1 GGGTGTGTGCGCGCC
EAAT2PyroSeq2 CCGCACACGCGCACG
Target sequence for pyrosequencing (1) T/G
Nucleotide dispensation order (1) CG
Target sequence for pyrosequencing (2) G/A
Nucleotide dispensation order (2) CA
Primer pair EAAT2PyroF-BIO/EAAT2PyroR were used to generate biotinylated PCR p
EAAT2PyroSeq1 (to detect g.-200C > A;-181A > C) and EAAT2PyroSeq2 (to detect g.-
nucleotides used as negative controls are underlined. The nucleotide change in theThe gel was washed twice in distilled water for 10 s and
then incubated in 0.5% glacial acetic acid (Fisher Scientific,
Loughborough, UK) and 10% molecular grade ethanol
(Sigma-Aldrich, St Louis, Missouri, UK). The gel was then
incubated in 0.1% silver nitrate (Sigma-Aldrich, St Louis,
Missouri, UK) solution for 20 min and rinsed with distilled
water twice. The gel was then washed with developing
solution, 1.5% NaOH (Fisher Scientific, Loughborough,
UK) and 0.15% molecular grade formaldehyde (Sigma-
Aldrich, St Louis, Missouri, UK) for 20 min. The gel
was fixed in 0.75% sodium carbonate (Fisher Scientific,
Loughborough, UK) solution for 10 min. The DNA bands
were visualized on a light box and the samples were
scored.
Generation of biotinylated PCR products for
pyrosequencing
Two sequence-specific primers (EAAT2PyroF-BIO and
EAAT2PyroR; Figure 1, Table 1) were designed to flank
all SNPs in the EAAT2 promoter using the software
provided by Qiagen Pyrosequencing, with the forward
primer biotinylated. PCR reactions contained 1× PCR
buffer (500 mM KCl, 100 mM Tris-HCl, pH 8.3), 1.5 mM
MgCl2, 200 μM of each dNTP, 100 pmol of each oligo-
nucleotide and 1 unit of high fidelity Taq polymerasetudy
duct (bp) Annealing T (°C) Annealing T (°C)
180 65 None
166 60 5′ Biotin
None
N/A None
N/A None
GGGGAGGCGGTGGAGGCCG/TCTG
TGCAGCGTGAGCGTGC
TGTGTGCGCGCC
GTGTGT
roducts flanking SNPs g.-200C > A; g.-181A > C and g.-168C > T. Primers
168C > T) were used for pyrosequencing. In the dispensation order the
Target sequence for pyrosequencing is indicated in bold.
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nostics Limited, West Sussex, UK) per reaction. Two
microlitres of genomic DNA (containing 4-6 ng DNA)
was used per reaction. Amplification was performed
with the following conditions: 95°C for 5 min; 50 cycles
of 94°C for 30 s, 60°C for 30 s and elongation at 72°C
for 30 s; followed by the final extension for 10 min at
72°C. Pyrosequencing and Sanger sequencing were
carried out as we described previously [29]. The target
sequence for analysis and the nucleotide dispensation
order for the pyrosequencing assay are shown in Table 1.
Purified PCR products were Sanger sequenced using
primer EAAT2R (Table 1).
Results
Analysis of the EAAT2 promoter using SSCP
A SNP was detected in the EAAT2 promoter at -181bp by
SSCP [11]. Since we were interested in this promoter re-
gion and already had considerable expertise in this method
[8], we used SSCP for our initial experiments. Although it
is not possible to predict the three-dimensional structure
from the primary sequence of the ssDNA [19], it is ex-
pected that the wild-type (WT/WT), mutant (MT/MT)
and heterozygote (WT/MT) would have a unique elec-
trophoretic mobility. Indeed, our SSCP result showed
the expected three distinct patterns (Figure 2, Lanes 1-3).
However, one sample (Figure 2, Lane 4) showed some
unexpected extra bands. Sanger sequencing of samples
scored based on their migration pattern as wild type
(n = 4, Lane 1), heterozygotes (n = 2, Lane 2), homozy-
gote mutants (n = 2, Lane 3) and the sample with an
unusual DNA migration (n = 1, Lane 4) revealed a pre-
viously unpublished polymorphism C to A transition
at -200bp (g.-200C >A), 19 bp upstream from the A to C
transition observed at -181 bp (g.-181A > C; [11]).Figure 2 SSCP patterns of the EAAT2 promoter genotypes.
Following PCR amplification, all samples were run on the same SSCP
gel and then visualised. The genotype of each sample determined by
Sanger sequencing is shown at the bottom of each lane. Note that all
these samples were wild type for g.-168C > T.Sanger sequencing also revealed that the following
additional genotypes exist (sequence is given in -200 bp
and -181bp order): A/A and A/A (Figure 2, Line 5); C/A
and A/A (Figure 2, Line 6); C/C and A/C (Figure 2,
Lane 7); A/A and A/C (Figure 2; Line 8); C/C and C/C
(Figure 2, Line 9). These variants did not migrate differ-
ently compared to the three main types (Figure 2, Lines
1-3), even when the SSCP running conditions were
further optimised suggesting that this technique is un-
suitable for the detection of all nine possible EAAT2
variants (Figure 2).
Optimization of pyrosequencing to detect all EAAT2
variants
The SSCP revealed that it was essential to get sequen-
cing data for all samples for accurate genotyping. Thus,
we used pyrosequencing, which is suitable for the amplifi-
cation of this short region and provides exact sequence
data for a large number of samples. Pyrosequencing was
optimised and evaluated using genomic DNA prepared
from blood from healthy adult volunteers. The initial
assay was designed to use the forward strand but this
approach was unsuccessful and the reading failed at
the SNP g.-181A > C (Figure 1, Figure 3A and B left
panel). Therefore, pyrosequencing was carried out on
the reverse strand which generated clear pyrograms
(Figure 3B right panel, Figure 4). Note that the se-
quence is given in reverse orientation.
Polymorphism analysis of the EAAT2 promoter using
pyrosequencing
Successful amplification was obtained in 209 samples
(87.5% success rate). Failure of the remaining samples
was likely due to low quality genomic DNA. Some of the
samples were 22 years old and showed DNA degradation
[29]. Overall in 89% of the samples the polymorphisms
g.-200C > A;-181A > C were inherited together (Table 2).
While the SSCP data indicates that the genotype distri-
bution of these SNPs is in Hardy Weinberg Equilibrium
(HW), the pyrosequencing results suggest the opposite
(Table 3). Measures of LD (D’ and r2), the non-random
association between alleles of different loci, are consist-
ent with the SNPs being linked (Table 3). The analysis
and interpretation of LD is difficult due to the lack of
HW and the presence of only one mutation at the -168
loci. Haplotype predictions are also shown in Table 4. A
100% concordance was observed when compared with
Sanger sequencing (n = 51 samples were sequenced with
both methods).
Comparison of sample genotyping using pyrosequencing
and SSCP
All nine sequence combinations have been success-
fully amplified and pyrosequenced (Figure 4; Note
Figure 3 Pyrograms using forward and reverse strands for sequencing. (A). SNPs g.-200C > A;-181A > C are indicated in rectangles on the
Sanger sequence traces. (B) Pyrograms of the same sample using forward (left panel) and reverse (right panel) primers. Arrows indicate the
region sequenced by both methods.
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adult control samples hence they are not presented in
Tables 2, 5 and 6). 239 samples from newborn infants
were initially used and 209 could be classified for SSCP
and pyrosequencing. Because different samples failed to
produce clear PCR products for SSCP and pyrosequenc-
ing, a total of 183 samples generated result with both
genotyping methods. With SSCP a total of 29 samples
(16%) were incorrectly genotyped (Table 5). While 51
samples were classified as homozygote wild type using
SSCP, pyrosequencing revealed that 25% of these sam-
ples do not belong to this group (Table 5). There was
surprisingly little error in the identification of the het-
erozygotes with SSCP and 96% of the samples were
correctly genotyped. In contrast, 12 homozygote mu-
tants (31%) were incorrectly identified (Table 5). We
also genotyped a small number of samples (n = 15) that
failed to produce a clear PCR product with the EAAT2F
and EAAT2R primers (hence could not be used for
SSCP, Figure 1) but resulted in clear pyrograms with
the EAAT2PyroSeq1 primer. A second SSCP was
carried out with EAAT2F and EAAT2PyroR primers
(Table 6) and found that with these primers similarproportion (20% versus 16%) of samples were misclassi-
fied as with the EAAT2F and EAAT2R primers.
To compare the concordance between SSCP and
pyrosequencing for a single SNP, SNP rs1835740 was
analysed in the same 239 samples. Three distinct SSCP
patterns were observed for the different genotypes
(Figure 5A) which were confirmed by a random Sanger
sequencing (Figure 5B) and pyrosequencing (Figure 5C)
of the whole cohort. The concordance rate between
SSCP and pyrosequencing was 94% for this SNP.
While our investigation was underway, a SNP g.-168C >
T was entered into the Database of Single Nucleotide
Polymorphisms (dbSNP), through the 1000 Genomes
Project [30] and was given a reference number of
(rs116392274:C > T; Human Build 137). This nucleotide
change is located in the EAAT2PyroSeq1 primer sequence
(Figure 1) and thus it could not be observed in the pyr-
ograms. However, using Sanger sequencing 51 samples
were sequenced with EAAT2R (Figure 1) and in all of
these samples only the C allele was observed at pos-
ition -168bp. Furthermore, a pyrosequencing assay was
developed to detect this g.-168C > T specifically (Figure 6).
Of the analysed samples, 213 were wild type (C/C) and
Figure 4 Predicted (top panels) and observed (bottom panels) pyrograms for EAAT2 promoter SNPs. The position of the SNPs is
highlighted in yellow boxes, the x-axis of each pyrogram indicates the order of reagent addition (E - enzyme, S -substrate and nucleotide A,G,T or
C); the y-axis shows the light intensity generated. The numbering of pyrograms corresponds to the haplotype numbers in Table 2. Note that all
these samples were wild type for g.-168C > T.
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MAF was 0.0023 in our cohort.
Discussion
Identification of additional SNPs in the EAAT2 promoter
We identified a polymorphism at -200bp in the EEAT2
promoter, 19bp upstream of the previously reported and
characterised polymorphism at -181bp (rs4354668:A > C
or g.-181A > C) [11]. Our data indicates that these
SNPs are in LD (Table 3). While our study was close to
completion, the g.-200C > A was added to the NCBI
SNP Database (1000 Genome Project, Human Build 137;
rs111885243:C >A) confirming our sequencing and pyrose-
quencing data. The MAF in our predominantly Caucasian
cohort for g.-200C > A and g.-181A > C is 0.46 and 0.49,
respectively. The Global MAF available from the SNP
Database are 0.39 and 0.41, respectively. More recently
another SNP in the EAAT2 promoter at position -168bp
was added to the NCBI SNP Database (Human Build137; rs116392274:C > T). In the 51 samples that we
sequenced only the C allele was present. Furthermore,
in the entire cohort (n = 214) only one T allele was
found in a heterozygous form (Table 2). To date, these
newly identified SNPs (g.-200C > A and g.-168C > T) have
not been investigated in association studies or cited in the
literature.
SSCP is not sensitive enough to reliably distinguish
between the various EAAT2 promoter genotypes
SSCP was used initially in this study because this
method has previously been applied to genotype exactly
the same region of the EAAT2 promoter [11]. We used
the same primers and PCR conditions as reported [11]
but modified the SSCP running conditions that provided
better separation of the DNA strands. Previously, ap-
proximately 2 h at a high voltage was used to resolve
the amplicons. In contrast, in the current study the
PCR products were resolved for 14 h at a relatively low
Table 2 Distribution of genotypes in the sample cohort
Genotype −200C > A −181A > C −168C > T Number &
proportion
1 C/C A/A C/C 42 (20%)
2 C/A A/C C/C 110 (53%)
3 A/A C/C C/C 34 (16%)
4 C/A C/C C/C 7 (3%)
5 A/A A/A C/C 4 (2%)
6 C/A A/A C/C 0
7a C/C A/C C/C 9 (4.5%)
7b C/C A/C C/T 1 (0.5%)
8 A/A A/C C/C 2 (1%)
9 C/C C/C C/C 0
n = 209
WT C = 0.54 A = 0.51 C = 0.997 Allele frequency
MT A = 0.46 C = 0.49 T = 0.002
Genotypes were identified by pyrosequencing (n = 209) and confirmed by
Sanger sequencing (n = 51). WT – wild type; MT – mutant.
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allowed better separation and visualization of the
ssDNA bands and lead to the identification of an add-
itional genotype (Figure 2, Lane 4). Sequencing of sev-
eral samples lead to the identification of g.-200C > A,
which was not reported in a previous study of this region
[11]. Our SSCP, pyrosequencing and Sanger sequencing
highlighted that although four clear migration patterns
can be seen (Figure 2, Lanes 1-4) several of the other
variants (Figure 2, genotypes 5-9,) could not be identi-
fied by SSCP. Note that the reproducibility of SSCP was
100% for the samples that were used as controls (oneTable 3 Hardy Weinberg equilibrium and LD variance for
the three EAAT2 SNPs using pyrosequencing or SSCP
Pyrosequencing SSCP
Hardy-Weinberg
for -168 p > 0.99 N/A
for -181 p = 0.0188 p = 0.4063
for -200 p = 0.0256 p = 0.3325
Lewontin’s D’
−168 and -181 0.49 N/A
−168 and -200 1 N/A
−181 and -200 0.94 1
r2
−168 and -181 0 N/A
−168 and -200 0 N/A
−181 and -200 0.79 0.99
Lewontin’s D’ and r2 both give ordinal measures of Linkage Disequilibrium
(LD). Please note only one mutation was found at -168 making interpretation
difficult for these associations.sample from each of the three main genotypes were
always run on each gel, in total n = 45 samples).
Studies using SSCP showed that the position of the
substitution within a codon and the nucleotide itself can
determine whether a SNP is detected [31]. A G to A or
G to T nucleotide change at the second position of a
codon caused a shift in ssDNA migration while failed to
do so if it occurred in the first position [31]. In our case
the SNP at -181bp is located on the second base, while
the SNP at -200bp is on the first base of a codon. Fur-
thermore, some nucleotide changes are detected at
lower rates than others. For example, A to C transver-
sions were detected at a higher rate (95%) compared to
C to A transversions (82%) [31]. The SNP at -200bp is a
C to A whilst the SNP at -181bp is an A to C transver-
sion. It is also documented that some point mutations
are not detected because of the nucleotide composition
(e.g. A + T or G + C richness) of a DNA region being
analysed [32]. Indeed, the EAAT2 promoter is highly
GC-rich (Figure 1). The amplicon used in both the pre-
vious study [11] and this study for SSCP analysis has a
GC content of ~73%. Furthermore, some mutations
may cause relatively small changes in electrophoretic
mobility [33] and might remain undetected by SSCP
[34-36]. These factors could explain that the SSCP pat-
terns for the EAAT2 promoter resemble that of a single
SNP instead of multiple SNPs. However, the banding
pattern does not fully correspond to the genotype of
the SNP at -181bp. While genotypes 5 and 8 followed
the -181bp SNP migration pattern, genotypes 6 and 7
resembled the migration of the -200bp SNP.
Based on the SSCP analysis, 25-31% of the WT/WT
and MT/MT samples were mis-classified (Table 5 and 6).
The previous study of the EAAT2 promoter region [11]
identified only three SSCP patterns in their cohort. How-
ever, considering the MAF of g.-200C >A and g.-181A > C
in the population (0.46 and 0.49 in the current predomin-
antly Caucasian cohort; 0.39 and 0.41 in the SNP Data-
base), it is expected that some of the additional variants
described here, should have been identified in the previous
study (Table 4). Indeed, a similar allele frequency and LD
levels are expected in Caucasian cohorts [37]. Furthermore,
numerous subsequent studies [27,28,38,39] understandably
continued with only investigating the association of this
single SNP (rs4354668:A > C or g.-181A > C) with various
diseases.
Many studies across different fields still use SSCP ex-
tensively as a genotyping method and about 1040 studies
are listed on PubMed that used SSCP since 2010 to date.
It is a simple, user-friendly, low cost method of SNP de-
tection which does not require specialist equipment and
can be adapted to a high-throughput format. It can
work very effectively when a single SNP is investigated
as we have demonstrated for an unrelated single SNP,
Table 4 Predicted haplotype frequencies in the cohort using pyrosequencing or SSCP
Pyrosequencing
SNP Haplotype C allele Total alleles
−168 C > T T T T T C C C C 417 418
−181 A > C A A C C A A C C 204 418
−200 C > A A C A C A C A C 225 418
% 0.0 0.0 0.0 0.2 1.5 49.8 44.6 3.9
SSCP
SNP Haplotype C allele Total alleles
−181 A > C A A C C 208 414
−200 C > A A C A C 205 414
% 0.2 49.5 50.2 0.0
(Total number of ‘C’ alleles is indicated).
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highlight that SSCP cannot always be used effectively
when several SNPs are located in the target sequence.
Although it is well recognised that a representative sam-
ple with distinct SSCP pattern needs to be sequenced to
validate the method, it is also crucial that the entire
sequence of the PCR product used for SSCP is scruti-
nised carefully. Generation of shorter PCR products
for SSCP can sometimes help to uncover previously
unnoticed variants [36,40]. If SSCP is used for genotyp-
ing (not for mutational screening) and all SNPs in the
regions are known, covering some of them with primers
may eliminate them from the SSCP pattern making the
analysis of the remainders easier. The PCR products for
the EAAT2 promoter are already short, generating even
shorter targets thus would not solve the problem seen
with this particular target sequence but might offer
solution for other troublesome targets.
Pyrosequencing as an alternative to detect closely
positioned SNPs
In our study g.-200C > A;-181A > C could simultaneously
be analysed by pyrosequencing (Figures 3, 4 and Table 2).
The detection limit of this method is dependent on how
well the dispensation profile can be set up. This in turn
depends on the nucleotide change within the SNP andTable 5 Comparison of genotypes identified by SSCP and pyr
SSCP
Genotype 1 2 3
1. WT/WT (n = 51) 38 (74.5%) 1 (1.9%) 0.0
2. WT/MT (n = 92) 0.0 88 (95.6%) 2 (2.2%)
3. MT/MT (n = 39) 0.0 6 (15.3%) 27 (69.2%)
4. (n = 1) 0.0 0.0 0.0
n = 183
For the SSCP EAAT2F and EAAT2R primers were used and pyrosequencing was don
correctly identified by both methods are indicated in bold. The genotype numbersthe nucleotides adjacent to the SNP(s) [41]. Indeed, the
latter caused problems in the genotyping of g.-181A > C
using a primer in 5′-3′ orientation (Figure 3B, left panel).
A four C mononucleotide repeat precedes this SNP and
the non-linear light generation of the mononucleotide
repeat made it impossible for the software to interpret
the correct number of incorporated identical nucleo-
tides [42,43] and as a consequence the assay failed at
the g.-181A > C SNP (in 100% of the 96 samples ana-
lysed). This problem was overcome by re-designing the
assay on the reverse strand and sequencing the nucleotide
change prior to the C mononucleotide repeats (Figure 3B,
right panel). Similarly, g.-168C > T was also sequenced
on the reverse strand (Figure 1). Both pyrosequencing
assays generated sequences immediately downstream of
the primer (Figure 1, 3 and 6), which cannot be achieved
with Sanger sequencing that lays a reading gap of 20-30
bp from the sequencing primer [44]. Pyrosequencing can
only analyse a few positions simultaneously [41], which
was the main reason for developing two separate assays to
detect g.-200C >A;-181A > C and g.-168C > T (Figure 1).
This approach resulted in clear and distinguishable pyro-
grams for each genotype for each assay. g.-168C > T was
found in a heterozygote form in one infant with no clinical
evidence of white matter injury (Rajatileka et al. unpub-
lished observation). The MAF of the g.-168C > T (0.0023osequencing
Pyprosequencing
4 5 6 7 8 9
0.0 4 (7.8%) 0.0 8 (15.6%) 0.0 0.0
0.0 0.0 0.0 0.0 2 (2.2%) 0.0
6 (15.4%) 0.0 0.0 0.0 0.0 0.0
1.0 0.0 0.0 0.0 0.0 0.0
n = 183
e with EAAT2PyroSeq1 primer (Figure 1 and Table 1). The genotypes that were
indicated under pyrosequencing corresponds to those used in Table 2.
Table 6 Comparison of genotypes identified by SSCP and pyrosequencing
SSCP PYROSEQUENCING
Genotype 1 2 3 4 5 6 7 8 9
1. WT/WT (n = 3) 2 (66.7%) 0.0 0.0 0.0 0.0 0.0 1 (33.3%) 0.0 0.0
2. WT/MT (n = 11) 0.0 9 (81.8%) 1 (9.1%) 0.0 0.0 0.0 1 (9.1%) 0.0 0.0
3. MT/MT (n = 1) 0.0 0.0 1 (100%) 0.0 0.0 0.0 0.0 0.0 0.0
n = 15 n = 15
For SSCP EAAT2F and EAAT2Pyro primers were used and pyrosequencing was done with EAAT2PyroSeq1 primer. The genotypes that were correctly identified by
both methods are indicated in bold.
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http://www.biomedcentral.com/1471-2156/15/80in our study and 0.017 on the SNP Database) is very low
in the general population which makes it challenging to
assess in association studies. SNP-SNP interactions have
been suggested to have a great impact on unveiling the
underlying mechanism of complex diseases [45]. Thus,
future clinical investigations of the impact of g.-200C >
A;-181A > C on the promoter function of EAAT2 and
their association with various diseases will need to be
assessed simultaneously.
Currently, the detection of g.-200C >A;-181A > C cost
£1.79 and £1.43 by pyrosequencing and SSCP, respectively.Figure 5 Detection of an unrelated SNP, rs1835740, by SSCP, Sanger
determined by Sanger sequencing is shown at the bottom of each lane. (B) S
the SNP on the pyrogram is highlighted in yellow boxes.For pyrosequencing the cost includes all reagents and
a charge for the use of the pyrosequencer. For SSCP
the cost was calculated from the reagents and Sanger
sequencing of 10% of the samples. Following PCR
amplification, the pyrosequencing required 1 h prepar-
ation time and 21 min run time for the two SNPs for
96 samples. For a single SNP (such as rs1835740:C > T)
the run time is usually ~10 min for 96 samples. In con-
trast, SSCP analysis of 100 samples requires 2-3 h
post-PCR preparation time, 12-16 h gel electrophoresis
and 0.45-1.5 h silver staining. In addition, at least 10%sequencing and pyrosequencing. (A) Genotype of each sample
NP is indicated in rectangles on the Sanger sequence. (C) The position of
Figure 6 Detection of the SNP in -168bp (g.-168C > T) in the EAAT2 promoter. Pyrogram (A) and Sanger sequencing (B) of the homozygote
WT and heterzygote samples.
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http://www.biomedcentral.com/1471-2156/15/80of the samples need to be prepared for Sanger sequen-
cing. Whilst pyrosequencing provides a less labour
intensive, low cost and high throughput platform to
genotype samples, in laboratories with no access to this
facility SSCP may be used reliably for genotyping if (i)
all mutations in the region are known, (ii) the SSCP
genotype readout is validated by another method,
and (iii) in case of two SNPs in the region the indica-
tive bands for both mutations are clearly and easily
distinguishable.
Conclusion
Our data suggest that SSCP cannot always detect reliably
several closely located SNPs. Furthermore, caution is
needed in the interpretation of the association studies
linking only one of the co-inherited SNPs in the EAAT2
promoter to human diseases.Competing interest
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